« Back to Record
Citation APA

Huober, J., Holmes, E., Baselga, J., de Azambuja, E., Untch, M., Fumagalli, D., Sarp, S., Lang, I., Smith, I., Boyle, F., Xu, B., Lecocq, C., Wildiers, H., Jouannaud, C., Hackman, J., Dasappa, L., Ciruelos, E., Toral-Peña, J. C., Adamchuk, H., Hickish, T., de la Peña, L., Jackisch, C., Gelber, R., Piccart-Gebhart, M., & Di Cosimo, S. (2019). Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. European journal of cancer, 118, 169-177. doi:10.1016/j.ejca.2019.04.038


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/296554

Huober, J., Holmes, E., Baselga, J., de Azambuja, E., Untch, M., Fumagalli, D., Sarp, S., Lang, I., Smith, I., Boyle, F., Xu, B., Lecocq, C., Wildiers, H., Jouannaud, C., Hackman, J., Dasappa, L., Ciruelos, E., Toral-Peña, J. C., Adamchuk, H., Hickish, T., de la Peña, L., Jackisch, C., Gelber, R., Piccart-Gebhart, M., & Di Cosimo, S. (2019). Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. European journal of cancer, 118, 169-177. doi:10.1016/j.ejca.2019.04.038